Tag Archives: Poseida R&D

Clinical Results from P-MUC1C-ALLO1 and P-BCMA-ALLO1; Novel Allogeneic CAR-T (P-ckit-ALLO1) for AML; Upcoming Milestones for Poseida; Poseida’s R&D Day Summary

On Wednesday, February 22, Poseida held its R&D day (press release / presentation) highlighting clinical results from P-MUC1C-ALLO1 (allogeneic MUC1-C CAR-T) in solid tumors and P-BCMA-ALLO1 (allogeneic BCMA CAR-T) for r/r MM. Additionally, management noted that P-CD19CD20-ALLO1’s (allogeneic CD19 x CD20 CAR-T) IND filing is expected in mid-2023 and presented a novel allogeneic CAR-T (P-ckit-ALLO1) for AML. Below, Celltelligence provides insights on Poseida’s clinical results, while discussing the potential of its more novel allogeneic assets.

About The Author

The Celltelligence Team

Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.


You’ll be able to access the full article from your Celltelligence Library after signing up.